COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00376090
Recruitment Status : Completed
First Posted : September 14, 2006
Last Update Posted : October 16, 2017
Information provided by (Responsible Party):
U.S. Army Medical Research and Development Command

Brief Summary:
The purpose of this study is to determine the safety and the immune responses to the HIV vaccine candidate, MVA-CMDR. This vaccine was designed to induce immune responses to three HIV "passenger" genes encoded with the viral vector, MVA.

Condition or disease Intervention/treatment Phase
HIV Infections Biological: MVA-CMDR Biological: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase I Double-Blind, Randomized, Dose Escalating, Placebo-Controlled, Study of Safety and Immunogenicity of WRAIR/NIH Live Recombinant MVA-CMDR (HIV-1 CM235 Env/ CM240 Gag/Pol) Administered by Intramuscular (IM) or Intradermal (ID) Route In HIV-Uninfected Adults
Actual Study Start Date : July 2005
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Group I Vaccine Biological: MVA-CMDR
10^7 PFU IM, 1.0 mL

Placebo Comparator: Group I Placebo Biological: Placebo
1.0 mL IM

Experimental: Group II Vaccine Biological: MVA-CMDR
10^6 PFU ID, 0.1 mL

Placebo Comparator: Group II Placebo Biological: Placebo
0.1 mL ID

Experimental: Group III Vaccine Biological: MVA-CMDR
10^8 PFU IM, 1.0 mL

Placebo Comparator: Group III Placebo Biological: Placebo
1.0 mL IM

Experimental: Group IV Vaccine Biological: MVA-CMDR
10^7 PFD ID, 0.1 mL

Placebo Comparator: Group IV Placebo Biological: Placebo
0.1 mL ID

Primary Outcome Measures :
  1. Safety and Tolerability [ Time Frame: Study Day 0 through 8 months post-vaccination ]
    Evaluate the safety and tolerability of MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) administered by IM or ID injection to HIV uninfected adults

Secondary Outcome Measures :
  1. Immunogenicity [ Time Frame: Study Day 0 through Study Day 280 ]
    Evaluate the ability of MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) to induce HIV antigen specific cellular and humoral immune responses

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

A participant must meet all of the following criteria:

  • Low risk for HIV infection
  • 18 to 40 years at the time of enrollment and vaccinia naive
  • Good health
  • Availability for 12 months of participation.
  • Successful completion of the Test of Understanding
  • Able and willing to give informed consent.
  • HEMATOCRIT: WOMEN: 35 %-45 %; MEN 36 % - 49 %
  • White cell count: 3,000 - 11,000 cells/mm3
  • Platelets: 125,000 - 450,000 per mm3
  • Normal cardiac enzyme level at second Screening Visit
  • Urinalysis (UA) for protein and blood: negative or trace.
  • Normal liver function tests to include ALT/AST, alkaline phosphatase, GGT (< 1.25x institutional upper limits of normal) and CPK (< 480) and creatinine (< 1.25 mg/dL)
  • Negative serology for HIV infection
  • Any female volunteer must have a negative serum or urine pregnancy test at the screening visit as well as immediately prior to each vaccine/placebo vaccination, as well as verbal assurance that adequate birth control measures have been followed for 60 days prior to the first vaccine/placebo vaccination and will continue to be followed for at least 3months after the final vaccine/placebo vaccination. This means using any of the following methods: Birth control drugs that prevent pregnancy given by pills, shots or placed under the skin, Male or female condoms with or without a cream or gel that kills sperm, diaphragm or cervical cap with a cream or gel that kills sperm, or Abstinence

Exclusion Criteria:

A volunteer will be excluded if one or more of the following conditions apply.

A woman who:

  • Is pregnant.
  • Is breast-feeding.

Anyone who:

  • Is U.S. military personnel.
  • Acknowledges engaging in highest-risk behavior within six months of study entry
  • Has active tuberculosis or other systemic infectious process by review of systems and physical examination.
  • Has history of or known cardiac disease including any of the following: prior myocardial infarction (heart attack), angina pectoris, congestive heart failure, conduction disturbances, repolarization (ST segment or T wave) abnormalities, serious cardiac arrhythmias (ventricular tachycardia or ventricular fibrillation), cardiomyopathy, pericarditis, stroke or transient ischemic attack, chest pain or shortness of breath with activity (e.g. climbing stairs), valvular heart disease including mitral valve prolapse, or other heart conditions under the care of a doctor.
  • Has ECG on Screening Visit 2 with clinical significant findings, or features that would interfere with the assessment of myo/pericarditis (as determined by the contract ECG Lab) including any of the following: conduction disturbance (atrioventricular or intraventricular condition, left or right bundle branch block, AB block of any degree or QTc prolongation), repolarization (ST segment or T wave) abnormality, significant atrial or ventricular arrhythmia, frequent atrial or ventricular ectopy (e.g. frequent premature atrial contractions, 2 premature ventricular contractions in a row), ST elevation consistent with ischemia, or evidence of past or evolving myocardial infarction
  • Has history of seizure disorder, immunodeficiency, chronic illness, autoimmune disease, diabetes mellitus active malignancy or use of immunosuppressive medications.
  • Has evidence of psychiatric, medical and/or substance abuse problems during the past six months that the investigator believes would adversely affect the volunteer's ability to participate in the trial.
  • Has occupational or other responsibilities that would prevent completion of participation in the study.
  • Has received any live attenuated vaccine within 60 days of study entry.
  • Has used experimental therapeutic agents within 30 days of study entry.
  • Has received blood products or immunoglobulins in the past three months.
  • Has history of anaphylaxis or other serious adverse reactions to vaccines.
  • Has previously received an HIV vaccine or an MVA or vaccinia vaccine.
  • Has chronic or active Hepatitis B or Hepatitis C virus infection or active syphilis (positive RPR and FTA).
  • Has had an immediate type hypersensitivity reaction to eggs, egg products or neomycin/streptomycin (used to prepare MVA vaccine).
  • Is a study site employee.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00376090

Layout table for location information
United States, Maryland
US Military HIV Research Program
Rockville, Maryland, United States, 20850
Sponsors and Collaborators
U.S. Army Medical Research and Development Command
Layout table for investigator information
Principal Investigator: Mary Marovich, MD, DTM&H US Military HIV Research Program
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: U.S. Army Medical Research and Development Command Identifier: NCT00376090    
Other Study ID Numbers: RV 158
A-12403 ( Other Identifier: USAMRMC HSRRB )
WRAIR 1143 ( Other Identifier: WRAIR HURC )
First Posted: September 14, 2006    Key Record Dates
Last Update Posted: October 16, 2017
Last Verified: October 2017
Keywords provided by U.S. Army Medical Research and Development Command:
MVA vector
HIV vaccine
HIV preventative vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases